High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Tempus AI's founder-CEO reduced an indirect stake by about 4% through a pre-scheduled trading plan, retaining roughly 6.5 million shares as the company pursues a major acquisition.
Tempus AI Inc (TEM) reports strong Q2 2026 results with record revenue, FDA approval for xT CDx, and a major BioNTech partnership, driving a raised outlook for 25% annual growth.
Tempus (TEM) delivered earnings and revenue surprises of +69.23% and +0.40%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Cathie Wood, CEO of Ark Investment Management, is known for buying her favorite growth stocks during sharp pullbacks. That's exactly what she's doing with Tempus AI (TEM) after the healthcare technology stock tumbled 14% over the past week. In 2025, the flagship Ark Innovation ETF gained ...
Tempus (TEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tempus AI (NasdaqGS:TEM) agreed to acquire cancer monitoring company Personalis in a deal valued at about US$1.5b. The transaction is focused on expanding Tempus AI's presence in minimal residual disease (MRD) testing and precision oncology. The company plans to combine Personalis' MRD technology with its existing AI driven precision oncology platform. For investors following Tempus AI, this deal highlights how central MRD testing and precision oncology have become in cancer care. Tempus AI...
Tempus will pay a 5.6% premium to integrate Personalis' cancer-testing platform into its AI-enabled oncology business.
Tempus AI (TEM) agreed to acquire cancer test maker Personalis (PSNL) in a $1.5 billion deal that Ne
Tempus AI, a healthcare tech company, is a favorite of investor Cathie Wood. Personalis does cancer testing.
Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.
Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.
Tempus AI stock has jumped 18.6% over the past week, yet the valuation picture is mixed, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while the broader checks suggest the shares are not a clear bargain. The 18.6% gain in the past week signals that expectations around Tempus AI have been reset quickly. This can leave new buyers with less room for error if sentiment cools. Strong revenue growth and expanding data and AI partnerships can support long...
Tempus AI, Inc. (NASDAQ:TEM) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On. On June 11, 2026, Tempus AI, Inc. (NASDAQ:TEM) announced that a multi-center validation of its artificial intelligence ECG software for predicting one-year atrial fibrillation or flutter risk was published in Heart Rhythm. The company stated the […]
Tempus AI Inc. (NASDAQ:TEM) is one of the 9 Stocks Crushing the Market With Surging Returns. Tempus AI saw its share prices jump by 10 percent on Thursday to finish at $52.56 apiece, as investors cheered its formation of a consortium alongside two health institutions to support the development of an open-source digital pathology platform […]
Tempus AI, Inc. (NASDAQ:TEM) ranks among the best short squeeze stocks to invest in. Following the company’s first-quarter results, H.C. Wainwright reduced its price target for Tempus AI, Inc. (NASDAQ:TEM) to $64 from $95 while retaining a Buy rating on the company’s shares. Tempus AI, Inc. (NASDAQ:TEM) posted total revenue of $348.1 million in Q1, […]
In recent days, Tempus AI announced a string of oncology-focused product advances, including FDA approval of its xT CDx tumor-only sequencing assay, major upgrades to its AI-enabled Next and Hub platforms, and new tools like Preview, Lens, and the ArteraAI Prostate Test (mHSPC) that deepen its role in precision cancer care. Taken together, these moves highlight Tempus AI’s effort to turn its multimodal data and foundation models into end-to-end clinical and biopharma solutions, from faster...
Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest trends among some of the most widely followed high-short-float stocks. Using the data from our partner Ortex.com, which utilizes the latest information from stock lenders to estimate short interest changes for thousands of publicly traded companies, this report will screen for some of biggest changes in short interest as a percentage of free float and days-to-cover ratios while also consi
Tempus AI, Inc. (NASDAQ:TEM) is one of the 10 Best ARK Stocks to Buy Right Now. On May 14, Tempus AI, Inc. (NASDAQ:TEM) announced a collaboration with Bristol Myers Squibb to maximize clinical trials. The partnership will use multimodal data and AI to improve trial design and boost the probability of technical and regulatory success […]
We just covered Cathie Wood’s 11 Biggest AI and Data Center Stock Picks. Tempus AI Inc. (NASDAQ:TEM) ranks #5 (see Cathie Wood’s 5 Biggest AI and Data Center Stock Picks). Cathie Wood’s Stake: $446,275,249 Tempus AI Inc. (NASDAQ:TEM) is an AI healthcare play in Cathie Wood’s portfolio. It’s a healthcare diagnostics and data platform that builds large-scale […]
Beneath the headline noise of a Q1 2026 beat and raised guidance, the critical insight for Tempus AI lies in a structural tug of war between an accelerating data moat and a currently elevated cost structure. The market is focusing on the 36% year over year top line growth to $348.1 million. The true alpha driver is hidden within the unit economics of the Data and Applications segment. This division is actively shifting the company from a traditional diagnostics provider to a recurring revenue he
Tempus (TEM) delivered earnings and revenue surprises of +38.10% and +0.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
In April 2026, the Keck School of Medicine of USC and Keck Medicine of USC announced a broad collaboration with Tempus AI to embed its genomic testing, AI tools, and data platform across more than 1.5 million annual patient visits in their Southern California network. This partnership not only expands Tempus AI’s clinical footprint but also deepens its access to real-world oncology data, reinforcing the company’s core data-network advantage in precision medicine. With this USC collaboration...
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of -89.47% and +4.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Is TEM a good stock to buy? We came across a bullish thesis on Tempus AI, Inc. on Joe Gannon’s Substack by Gannon Capital. In this article, we will summarize the bulls’ thesis on TEM. Tempus AI, Inc.’s share was trading at $56.78 as of April 20th. TEM’s trailing P/E was 39.30 according to Yahoo Finance. Tempus AI, Inc. operates as […]
TEM and ILMN battle in precision oncology, but stronger stock gains, valuation and earnings outlook position ILMN as the more compelling pick now.
The blended fair value estimate for Tempus AI has been adjusted slightly, moving from US$72.73 to US$72.40 as part of the latest round of analyst model updates. This small shift sits against a mixed research backdrop, where some firms are lifting targets after Q4 while others are trimming estimates and highlighting questions around data monetization, partnerships and the balance between growth and visibility. As you read on, you will see how to track these moving pieces and what to watch as...
TEM faces pressure ahead of Q1 earnings as macro headwinds, high valuation and estimate trends cloud its near-term investment appeal.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
